BioMarin Pharmaceutical (HAM:BM8) Construction In Progress: €0 Mil (As of Mar. 2026)


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
79 GF Score
Price €50.60
GF Value €77.13
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Construction In Progress?

BioMarin Pharmaceutical HAM:BM8 -1.02% 79 Construction In Progress is €0 Mil as of Mar. 2026. GuruFocus rates HAM:BM8 with a GF Score™ of 79/100 and a GF Value™ of €77.13. The stock has 3 warning signs investors should review.

BioMarin Pharmaceutical's quarterly construction in progress increased from Sep. 2025 (€0 Mil) to Dec. 2025 (€115 Mil) but then declined from Dec. 2025 (€115 Mil) to Mar. 2026 (€0 Mil).

BioMarin Pharmaceutical's annual construction in progress declined from Dec. 2023 (€92 Mil) to Dec. 2024 (€86 Mil) but then increased from Dec. 2024 (€86 Mil) to Dec. 2025 (€115 Mil).

BioMarin Pharmaceutical Construction In Progress Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Construction In Progress Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.02 135.35 91.71 86.21 115.21

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 115.21 0.00
HAM:BM8
79GF Score
BioMarin Pharmaceutical Inc HAM:BM8
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0 Mil mean?
BioMarin Pharmaceutical (HAM:BM8) has a Construction In Progress of €0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Construction In Progress too high?
BioMarin Pharmaceutical's current Construction In Progress is €0 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Construction In Progress compare to CYTK and ARWR?
BioMarin Pharmaceutical's Construction In Progress of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Construction In Progress is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current Construction In Progress of €0 Mil. The stock's GF Value™ is €77.13, compared to a current price of €50.60 — trading 34.4% below its estimated fair value. The current Construction In Progress is €0 Mil. BioMarin Pharmaceutical's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current Construction In Progress is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €50.60 is trading 34.4% below its estimated GF Value™ of €77.13.

Key valuation signals for HAM:BM8:

  • Construction In Progress: €0 Mil
  • GF Value™: €77.13 vs. price of €50.60 (34.4% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score

Get the complete analysis for HAM:BM8

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.60
Price
€77.13
GF Value